An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.
about
Dinosaurs and ancient civilizations: reflections on the treatment of cancerProstate cancer relevant antigens and enzymes for targeted drug deliveryIdentification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM)PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectivesuPAR and cathepsin B-mediated compartmentalization of JNK regulates the migration of glioma-initiating cellsPathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situFirst (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.Epithelial and stromal cell urokinase plasminogen activator receptor expression differentially correlates with survival in rectal cancer stages B and C patients.Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA studyCrosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.Imaging active urokinase plasminogen activator in prostate cancer.S-adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applicationsThe interconnectedness of cancer cell signaling.uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgeryThe many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single targetUrokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapyDevelopment of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.Antibody therapeutics for treating prostate cancer: where are we now and what comes next?The dual role of TLR3 in metastatic cell line.Surface Toll-like receptor 3 expression in metastatic intestinal epithelial cells induces inflammatory cytokine production and promotes invasiveness.LRP5 knockdown: effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integrationMultifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
P2860
Q24628746-8929BFF3-338D-44CB-8B95-064EF22A927AQ27013843-A94F699F-B805-4085-A638-F852190900FBQ27681464-C5BE0F02-79FE-4713-8DAF-C2F547A8D461Q28078479-EF50CD13-232F-4BAF-9F3B-D4FF4E0E4A2FQ28237374-20C4561D-6D92-43FA-9037-0BE7B6D3BE68Q29994686-E3A216EE-3E07-4C69-92DA-5A55B4E5559AQ34442512-62594A6E-488B-4423-AFED-4A08210463BCQ34777224-61A66462-F463-442A-9C87-54A3C9FCD17FQ34802502-6A1B380F-9326-4F04-B220-4482F6C75EACQ35097486-833751E5-B514-4172-9192-B48E04956885Q35151053-B554684C-A178-49E7-A29F-28EAF1A9BF09Q35229306-D7435D9D-DA07-42C6-9DED-3357E9A33911Q35251858-379D70C0-FF76-4177-8ECE-768C0FB426D8Q35602148-57373288-A8C4-4EEE-A945-CE81DC263B43Q35669733-C8C8D433-3EF5-444D-B9A9-86E4F6D7FD8DQ35987322-C19444FA-52E2-4D69-A06C-38AB9F8C8F45Q36997621-1F9CD896-16E0-49A1-9B21-4DC4FE3D4C31Q36997627-9E8C7D28-926C-4AAD-8E7C-F42C39286720Q37895294-A8352BBC-D7E9-4FBB-AFF2-3E767F82D1EAQ38093654-53F4A740-FA3A-4899-BFFD-873ECEBBB1AAQ39000185-D1740C0B-8F89-4380-AF41-6AECCD4762B3Q39511419-0D91F071-064A-428E-9793-FF426CC862E1Q41706515-A37D8C16-133C-446F-BC1D-E7E539BDE5E5Q41873508-CDD253F2-DF07-4E7D-B2E7-09B5B685DC83Q41879186-B93F1FA3-BAFB-492C-9C0D-60643FD339A3Q54960825-E283A2E1-F572-4BA6-98D0-9FFE3C0B015A
P2860
An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
An anti-urokinase plasminogen ...... tastasis in vitro and in vivo.
@en
An anti-urokinase plasminogen ...... tastasis in vitro and in vivo.
@nl
type
label
An anti-urokinase plasminogen ...... tastasis in vitro and in vivo.
@en
An anti-urokinase plasminogen ...... tastasis in vitro and in vivo.
@nl
prefLabel
An anti-urokinase plasminogen ...... tastasis in vitro and in vivo.
@en
An anti-urokinase plasminogen ...... tastasis in vitro and in vivo.
@nl
P2093
P2860
P356
P1433
P1476
An anti-urokinase plasminogen ...... etastasis in vitro and in vivo
@en
P2093
Andrew P Mazar
Ani Arakelian
Christopher A Kerfoot
David E Shaw
Lisa M Dauffenbach
Maria Luisa Valentino
P2860
P304
P356
10.1593/NEO.10296
P577
2010-10-01T00:00:00Z